Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q4 FY2025-26 Earnings Presentation
19 slides from Gujarat Themis Biosyn's earnings presentation, May 25, 2026
Slide 1: Investor Presentation Cover Letter to Exchanges
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2026-27/19 25 th May, 2026 Corporate Relationship Department Listing Department BS
Slide 2: Gujarat Themis Biosyn Limited Investor Presentation Q4 & FY2025-26
Gujarat Themis Biosyn Limited Investor Presentation Q4 & FY2025-26
Slide 3: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 4: Management Commentary
Click to edit MasterComment Management title style Commenting on the result, Dr. Sachin Patel, Managing Director, said: “We are pleased to report that the company concluded the fiscal year on a strong note, successfully sustaining our growth trajectory. Sales volumes remained robust, driven by stead
Slide 5: Sanofi to Acquire Select Product Portfolio
Click to edit Master Agreement withtitle style Sanofi to Acquire Select Product Portfolio Portfolio Structure DEAL SNAPSHOT TB & Anti-Infective Focus Asset-Light Model ~EUR 158 Mn 13 established brands across tuberculosis & anti- Structured as asset acquisition (Brands + MAs + Deal Value | Funded vi
Slide 6: Acquisition of MicroBiopharm Japan Co., Ltd.
Click to edit Master Acquisition title style of MicroBiopharm Japan Co., Ltd. Wider Product Portfolio & Therapeutic Coverage Technology DEAL SNAPSHOT Expanded portfolio of products & therapy Novel Biotech Platforms JPY 21.5 Bn areas Deal Value | ~INR 1,300 Crore Broadens GTBL's API and intermediates
Slide 7: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 42.3 43.4 44.2 37.7 35.9 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 60% 49.5% 49.1% 16 40% 20 42.5% 43.8% 50% 33.7% 14 31.8% 35% 38.8% 28.7% 40% 12 25.3% 30% 15 24.6
Slide 8: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Rs. Cr. Q4 FY26 Q4 FY25 YoY% Q3 FY26 Income from Operations 44.23 37.74 43.37 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 44.23 37.74 17.22% 43.37 Cost of Materials Consumed 10.05 6.85 6.62 Changes In Inventory (6.
Slide 9: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Rs. Cr. FY26 FY25 YoY% Income from Operations 165.82 150.80 Other Operating Income 0.00 0.00 Total Income from Operations 165.82 150.80 9.96% Cost of Materials Consumed 30.43 25.78 Changes In Inventory (9.03) (1.27) Employee Cost 16.51 12.6
Slide 10: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 169.82 165.82 148.39 150.80 114.85 FY21-22 FY22-23 FY23-24 FY24-25 FY25-26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 90 50.5% 49.6% 51% 80 46.4% 45.6% 50% 70 39.1% 45% 45.7% 38.0% 70 49% 60 34.8% 40% 32.3% 60 2
Slide 11: Balance Sheet Highlights
Click to edit Master Balance title style– As on 31st March 2026 Sheet Highlights Rs. Cr. As on 31st As on 31st Rs. Cr. As on 31st As on 31st Mar, Total Equity & Liabilities Mar, 2025 Mar, 2026 Total Assets Mar, 2025 2026 Shareholders Funds 248.38 287.77 Non Current Assets 249.34 414.64 Share Capital
Slide 12: Key Balance Sheet Ratios
Keyedit Click to Balance Sheet Master Ratios title style RoCE(%)* RoA(%)** 36% 35% 57.9% 27% 52.1% 39.4% 16% 23.6% 9% 14.5% FY21-22 FY22-23 FY23-24 FY24-25 FY25-26 FY21-22 FY22-23 FY23-24 FY24-25 FY25-26 RoE(%)*** 42.2% 38.9% 29.4% 19.6% 16.2% FY21-22 FY22-23 FY23-24 FY24-25 FY25-26 Company has been
Slide 13: Among India's few fermentation based intermediate manufacturers
Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturers in pharmaceutical field State of Art Manufacturing Facility ▪ Incorporated in 1981 as joint ▪ Plant in Vapi (Gujarat) sector Company with GIIC
Slide 14: Product Portfolio – Growing at a fast pace
Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin ▪ An intermediate for Rifamycin S ▪ An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t
Slide 15: Expansion Strategy to Spur Growth
Click to edit Master Expansion titletostyle Strategy Spur Growth Capex Research & Development Forward Integration Fermentation ❖ Ventured into API production as ❖ New Product Development part of forward integration ❖ Expanding fermentation capacity ❖ R&D Unit Commissioned, as per strategy ❖ Addition
Slide 16: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 15
Slide 17: Our Way Ahead
Click to Ouredit Way Master Aheadtitle style ▪ In process of identifying new products which have good domestic & export New Product Development & potential ▪ Company strategizing to move up the value chain through forward integration into Forward Integration API – recently began commercial operation
Slide 18: Hybrid Renewable Power Project
Click to edit Renewable Hybrid Master titlePower styleProject Strategic ESG & Cost Optimization Initiative ➢ Advancing the Company’s ESG roadmap Capacity through increased adoption of renewable Wind + Solar Hybrid energy for captive consumption, thus ~ 18 MW lowering carbon footprint ➢ Hybrid wind–s
Slide 19: Thank You
Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Krupesh Patel, CFO Mr. Rahul Trivedi Ms. Saloni Nagvekar krupesh.patel@themismedicare.com rahul.trivedi@adfactorspr.com
Gujarat Themis Biosyn — Q4 FY2025-26 Earnings Presentation on 6ix